Novavax signs Covid-19 vaccine supply deal with India's Serum Institute

Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialisation of its Covid-19 vaccine candidate.

CORONAVIRUS SPECIAL COVERAGE ONLY ON DH

The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the "Pandemic Period" in all countries other than those designated by the World Bank as upper-middle or high-income countries.

The deal was signed on July 30, according to an SEC filing by Novavax.

For latest updates and live news on coronavirus, click here

On Tuesday, Novavax reported that its experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial and that it could start a large pivotal Phase III trial as soon as late September.